🔗 Share this article

Given that the US proceeds with unprecedented changes to its immunization recommendations, a particular individual has surfaced unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning Covid vaccinations in the global health crisis and has zeroed in on possible deaths after COVID-19 immunization in her brief position at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Program

Health officials were set to reveal radical revisions to the childhood immunization program recently, bringing the US with the Danish vaccine program, sources say – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. This reveal has been postponed until the new year.

Rather than the top vaccines chief, Dr. Høeg is listed to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

A New Direction at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US to become more in line with Denmark, a society with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Høeg has no apparent track record in medication creation, regulation or management, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in drug approvals.”

Former heads of CBER would “understand legal statutes and the science of medication creation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that previous people who ran the center have had.”

The drug center has an vast workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the new drug program, but the generic program authorizes a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one need to be managed,” Dr. Woodcock noted. “The thing you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a substantial administrative element to the job, which oversees in excess of 5,000 employees. “It is a enormous leadership role, if you do it right,” the former official added.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's credentials and whether this selection signifies more teamwork among regulatory chiefs on vaccines, a representative stated that the “concerns are based on flawed assumptions”.

“Her experience matches the duties of her role,” the official explained, noting the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a disputed one-day medication authorization process that allegedly concerned her former heads. “How are these drugs being chosen for this voucher program? Who makes the choices?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the FDA appears to be shifting towards less stringent regulations of pharmaceuticals, except for shots.”

Documented Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, past, Howard said. She published a study using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming administration encompassed changing guidelines for novel immunizations and halting “non-essential” immunizations, she stated following the vote on a podcast. At the FDA, Dr. Høeg has reportedly suggested barring adolescent males from receiving Covid vaccines.

“She’s an complete dogmatist who begins with her preconceived notions and works backwards to accommodate the evidence in a highly misleading, dishonest manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|